Clinical Trials Market 2027 By Phase, Study Design, Indication and Geography | The Insight Partners

Clinical Trials Market to 2027 - Global Analysis and Forecasts by Phase (Phase I, Phase II, Phase III, Phase IV); Study Design (Interventional, Observational, Expanded access); Indication (Autoimmune/inflammation, Pain management, Oncology, CNS condition, Diabetes, Obesity, Cardiovascular, Others) and Geography

Report Code: TIPRE00006203 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION

A clinical trial is a research study, where a group of people is given a test or treatment. Clinical trials study the safety and efficacy of tests and treatments. If the test or treatment is safe and meets regulatory requirements, then it is approved as a standard of care.

MARKET DYNAMICS

The Clinical trial market is anticipated to grow in the forecast, owing to the globalization of clinical trials, development of new treatments such as personalized medicine and increasing prevalence of infectious disease and new disease cases. In addition, increasing investments to develop new healthcare products is expected to offer significant growth opportunities in the market during the forecast period.

MARKET SCOPE

The "Global Clinical Trial market Analysis to 2027" is a specialized and in-depth study of the medical device industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the Clinical trial market with detailed market segmentation by phase, study design, indication and geography. The global Clinical trial market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Clinical trial market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global Clinical trial market is segmented on the basis of phase, study design, indication. Based on phase, the market is segmented as, phase I, phase II, phase III and phase IV. Based on the study design, the market is segmented into interventional, observational and expanded access. Based on indication, the market is segmented into autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Clinical trial market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Clinical trial market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Clinical trial market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Clinical trial market in these regions.

MARKET PLAYERS

The reports cover key developments in the Clinical trial market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others, such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved the way for the expansion of business and customer base of market players. The market payers from Clinical trial market are anticipated to lucrative growth opportunities in the future with the rising demand for Clinical trial market in the global market. Below mentioned is the list of few companies engaged in the Clinical trial market.

The report also includes the profiles of key Clinical trial market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of the last 3 years, key development in the past five years.

- IQVIA
- Parexel International Corporation
- Charles River Laboratories
- ICON plc
- SGS SA
- Chiltern International Ltd
- Syneos Health
- PRA Health Sciences
- Wuxi AppTec Inc
- Pharmaceutical Product Development, LLC

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Clinical Trials - By Phase
1.3.2 Clinical Trials - By Study Design
1.3.3 Clinical Trials - By Indication
1.3.4 Clinical Trials - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CLINICAL TRIALS LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CLINICAL TRIALS - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CLINICAL TRIALS - GLOBAL MARKET ANALYSIS
6.1. CLINICAL TRIALS - GLOBAL MARKET OVERVIEW
6.2. CLINICAL TRIALS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CLINICAL TRIALS - REVENUE AND FORECASTS TO 2027 - PHASE
7.1. OVERVIEW
7.2. PHASE MARKET FORECASTS AND ANALYSIS
7.3. PHASE I
7.3.1. Overview
7.3.2. Phase I Market Forecast and Analysis
7.4. PHASE II
7.4.1. Overview
7.4.2. Phase II Market Forecast and Analysis
7.5. PHASE III
7.5.1. Overview
7.5.2. Phase III Market Forecast and Analysis
7.6. PHASE IV
7.6.1. Overview
7.6.2. Phase IV Market Forecast and Analysis
8. CLINICAL TRIALS - REVENUE AND FORECASTS TO 2027 - STUDY DESIGN
8.1. OVERVIEW
8.2. STUDY DESIGN MARKET FORECASTS AND ANALYSIS
8.3. INTERVENTIONAL
8.3.1. Overview
8.3.2. Interventional Market Forecast and Analysis
8.4. OBSERVATIONAL
8.4.1. Overview
8.4.2. Observational Market Forecast and Analysis
8.5. EXPANDED ACCESS
8.5.1. Overview
8.5.2. Expanded access Market Forecast and Analysis
9. CLINICAL TRIALS - REVENUE AND FORECASTS TO 2027 - INDICATION
9.1. OVERVIEW
9.2. INDICATION MARKET FORECASTS AND ANALYSIS
9.3. AUTOIMMUNE/INFLAMMATION
9.3.1. Overview
9.3.2. Autoimmune/inflammation Market Forecast and Analysis
9.4. PAIN MANAGEMENT
9.4.1. Overview
9.4.2. Pain management Market Forecast and Analysis
9.5. ONCOLOGY
9.5.1. Overview
9.5.2. Oncology Market Forecast and Analysis
9.6. CNS CONDITION
9.6.1. Overview
9.6.2. CNS condition Market Forecast and Analysis
9.7. DIABETES
9.7.1. Overview
9.7.2. Diabetes Market Forecast and Analysis
9.8. OBESITY
9.8.1. Overview
9.8.2. Obesity Market Forecast and Analysis
9.9. CARDIOVASCULAR
9.9.1. Overview
9.9.2. Cardiovascular Market Forecast and Analysis
9.10. OTHERS
9.10.1. Overview
9.10.2. Others Market Forecast and Analysis
10. CLINICAL TRIALS REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Clinical Trials Overview
10.1.2 North America Clinical Trials Forecasts and Analysis
10.1.3 North America Clinical Trials Forecasts and Analysis - By Phase
10.1.4 North America Clinical Trials Forecasts and Analysis - By Study Design
10.1.5 North America Clinical Trials Forecasts and Analysis - By Indication
10.1.6 North America Clinical Trials Forecasts and Analysis - By Countries
10.1.6.1 United States Clinical Trials
10.1.6.1.1 United States Clinical Trials by Phase
10.1.6.1.2 United States Clinical Trials by Study Design
10.1.6.1.3 United States Clinical Trials by Indication
10.1.6.2 Canada Clinical Trials
10.1.6.2.1 Canada Clinical Trials by Phase
10.1.6.2.2 Canada Clinical Trials by Study Design
10.1.6.2.3 Canada Clinical Trials by Indication
10.1.6.3 Mexico Clinical Trials
10.1.6.3.1 Mexico Clinical Trials by Phase
10.1.6.3.2 Mexico Clinical Trials by Study Design
10.1.6.3.3 Mexico Clinical Trials by Indication
10.2. EUROPE
10.2.1 Europe Clinical Trials Overview
10.2.2 Europe Clinical Trials Forecasts and Analysis
10.2.3 Europe Clinical Trials Forecasts and Analysis - By Phase
10.2.4 Europe Clinical Trials Forecasts and Analysis - By Study Design
10.2.5 Europe Clinical Trials Forecasts and Analysis - By Indication
10.2.6 Europe Clinical Trials Forecasts and Analysis - By Countries
10.2.6.1 Germany Clinical Trials
10.2.6.1.1 Germany Clinical Trials by Phase
10.2.6.1.2 Germany Clinical Trials by Study Design
10.2.6.1.3 Germany Clinical Trials by Indication
10.2.6.2 France Clinical Trials
10.2.6.2.1 France Clinical Trials by Phase
10.2.6.2.2 France Clinical Trials by Study Design
10.2.6.2.3 France Clinical Trials by Indication
10.2.6.3 Italy Clinical Trials
10.2.6.3.1 Italy Clinical Trials by Phase
10.2.6.3.2 Italy Clinical Trials by Study Design
10.2.6.3.3 Italy Clinical Trials by Indication
10.2.6.4 Spain Clinical Trials
10.2.6.4.1 Spain Clinical Trials by Phase
10.2.6.4.2 Spain Clinical Trials by Study Design
10.2.6.4.3 Spain Clinical Trials by Indication
10.2.6.5 United Kingdom Clinical Trials
10.2.6.5.1 United Kingdom Clinical Trials by Phase
10.2.6.5.2 United Kingdom Clinical Trials by Study Design
10.2.6.5.3 United Kingdom Clinical Trials by Indication
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Clinical Trials Overview
10.3.2 Asia-Pacific Clinical Trials Forecasts and Analysis
10.3.3 Asia-Pacific Clinical Trials Forecasts and Analysis - By Phase
10.3.4 Asia-Pacific Clinical Trials Forecasts and Analysis - By Study Design
10.3.5 Asia-Pacific Clinical Trials Forecasts and Analysis - By Indication
10.3.6 Asia-Pacific Clinical Trials Forecasts and Analysis - By Countries
10.3.6.1 Australia Clinical Trials
10.3.6.1.1 Australia Clinical Trials by Phase
10.3.6.1.2 Australia Clinical Trials by Study Design
10.3.6.1.3 Australia Clinical Trials by Indication
10.3.6.2 China Clinical Trials
10.3.6.2.1 China Clinical Trials by Phase
10.3.6.2.2 China Clinical Trials by Study Design
10.3.6.2.3 China Clinical Trials by Indication
10.3.6.3 India Clinical Trials
10.3.6.3.1 India Clinical Trials by Phase
10.3.6.3.2 India Clinical Trials by Study Design
10.3.6.3.3 India Clinical Trials by Indication
10.3.6.4 Japan Clinical Trials
10.3.6.4.1 Japan Clinical Trials by Phase
10.3.6.4.2 Japan Clinical Trials by Study Design
10.3.6.4.3 Japan Clinical Trials by Indication
10.3.6.5 South Korea Clinical Trials
10.3.6.5.1 South Korea Clinical Trials by Phase
10.3.6.5.2 South Korea Clinical Trials by Study Design
10.3.6.5.3 South Korea Clinical Trials by Indication
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Clinical Trials Overview
10.4.2 Middle East and Africa Clinical Trials Forecasts and Analysis
10.4.3 Middle East and Africa Clinical Trials Forecasts and Analysis - By Phase
10.4.4 Middle East and Africa Clinical Trials Forecasts and Analysis - By Study Design
10.4.5 Middle East and Africa Clinical Trials Forecasts and Analysis - By Indication
10.4.6 Middle East and Africa Clinical Trials Forecasts and Analysis - By Countries
10.4.6.1 South Africa Clinical Trials
10.4.6.1.1 South Africa Clinical Trials by Phase
10.4.6.1.2 South Africa Clinical Trials by Study Design
10.4.6.1.3 South Africa Clinical Trials by Indication
10.4.6.2 Saudi Arabia Clinical Trials
10.4.6.2.1 Saudi Arabia Clinical Trials by Phase
10.4.6.2.2 Saudi Arabia Clinical Trials by Study Design
10.4.6.2.3 Saudi Arabia Clinical Trials by Indication
10.4.6.3 U.A.E Clinical Trials
10.4.6.3.1 U.A.E Clinical Trials by Phase
10.4.6.3.2 U.A.E Clinical Trials by Study Design
10.4.6.3.3 U.A.E Clinical Trials by Indication
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Clinical Trials Overview
10.5.2 South and Central America Clinical Trials Forecasts and Analysis
10.5.3 South and Central America Clinical Trials Forecasts and Analysis - By Phase
10.5.4 South and Central America Clinical Trials Forecasts and Analysis - By Study Design
10.5.5 South and Central America Clinical Trials Forecasts and Analysis - By Indication
10.5.6 South and Central America Clinical Trials Forecasts and Analysis - By Countries
10.5.6.1 Brazil Clinical Trials
10.5.6.1.1 Brazil Clinical Trials by Phase
10.5.6.1.2 Brazil Clinical Trials by Study Design
10.5.6.1.3 Brazil Clinical Trials by Indication
10.5.6.2 Argentina Clinical Trials
10.5.6.2.1 Argentina Clinical Trials by Phase
10.5.6.2.2 Argentina Clinical Trials by Study Design
10.5.6.2.3 Argentina Clinical Trials by Indication
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. CLINICAL TRIALS, KEY COMPANY PROFILES
12.1. IQVIA
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PAREXEL INTERNATIONAL CORPORATION
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. CHARLES RIVER LABORATORY
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ICON PLC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. WUXI APPTEC INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. PRA HEALTH SCIENCES
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SGS SA
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. SYNEOS HEALTH
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. CHILTERN INTERNATIONAL LTD
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. IQVIA
2. Parexel International Corporation
3. Charles River Laboratories
4. ICON plc
5. SGS SA
6. Chiltern International Ltd
7. Syneos Health
8. PRA Health Sciences
9. Wuxi AppTec Inc
10. Pharmaceutical Product Development, LLC